Uganda

Women and Families Initiative

The HIV Collaborative Fund, a community organization that raises funds to support treatment for people living with HIV/AIDS, and Johnson & Johnson are partnering in a Women and Families initiative, which focuses on HIV/AIDS treatment preparation services for women. These services include advocacy, treatment and adherence education, counseling on stigma and discrimination, skills-building workshops, and direct service delivery in each of the communities served. Thousands of women in communities throughout Sub-Saharan Africa have been reached over the past few years.

ViiV Healthcare Collaborative Research Program for Resource-Poor Settings

ViiV Healthcare is committed to the development of new molecules that target unmet medical needs in HIV. The treatment of children with HIV/AIDS remains a significant unmet medical need and there is a pressing need for new medicines to tackle problems such as drug resistance, complex treatment regimens, and side effects associated with current treatments.

ViiV Healthcare Access to ARVs

In the Least Developed Countries and sub-Saharan Africa GlaxoSmithKline has offered its HIV/AIDS medicines at not-for-profit (nfp) prices since 2001. ViiV Healthcare will maintain this commitment, and will include the additional products in its portfolio. All of ViiV Healthcare's ARVs are now available at not-for-profit prices to public sector customers and not-for-profit organizations in all Least Developed Countries and all of sub-Saharan Africa - 64 countries in total.

Sikiliza Leo Project, Uganda

Johnson & Johnson, its Tibotec subsidiary and the African Medical Research Foundation help the Ugandan NGO Sikiliza Leo to provide HIV testing, counseling, treatment and care in rural Uganda. Since March 2003, HIV testing and counseling have been offered to 3,586 community members, of whom 559 have tested positive for HIV. A total of 272 persons receive Home Based Care and a first group of 20 are now receiving ARV therapy.

Sigma-Tau & AMREF: 'Uganda Project'

Sigma-Tau supports the African Medical Research Foundation (AMREF) in implementing the 'Uganda Project', a vaccination and medical training program in Northern Uganda, in the areas most affected by the civil war of the 1990s. The main aim of the project is to vaccinate more than 3,000 Ugandan children against the six most common childhood diseases (tuberculosis, diphtheria, tetanus, poliomyelitis, hepatitis B and measles). At the same time, it also aims to provide medical training for local health workers, thus furnishing both immediate and long-term support for health development.

Sanofi-aventis Sleeping Sickness Program

Sleeping sickness has reemerged in Africa as a major health threat. In 2001, sanofi-aventis committed USD 25 million over the years 2001-2006 to help the World Health Organization (WHO) to implement a strategy of adequate medicine supplies, disease surveillance and management, plus R&D for new treatments. After five years, WHO and sanofi-aventis' efforts were estimated to have saved 110,000 lives. In 2006, the company renewed its contract with the WHO and expanded it to address several additional 'most neglected diseases' (see separate entry).

Sanofi-aventis - DNDi Malaria Medicine

In April 2005, sanofi-aventis signed an agreement with Drugs for Neglected Diseases initiative (DNDi) to develop a new medicine against malaria, in response to a call from the World Health Organization (WHO) for malaria be treated by drug combinations to combat resistance. DNDi and sanofi-aventis have developed a fixed-dose combination (FDC) of two antimalarial compounds, artesunate and amodiaquine (ASAQ) that is easier to use and more affordable than any other combination currently available.

Regional Psychosocial Support Initiative

In Southern and East Africa, the Novartis Foundation aims to improve livelihoods and future prospects of children and adolescents affected by HIV/AIDS.

PMTCT: Abbott Rapid HIV Test Donation Program

Each year, approximately 800,000 babies around the world become infected with HIV during their mothers´ pregnancy, during birth or through breastfeeding.

Pfizer Global Health Fellows

The Pfizer Global Health Fellows program utilizes the professional expertise of Pfizer employees through specialized volunteer assignments with nonprofit organizations to improve health care services for underserved communities around the world. Since 2003, more than 230 employees with a range of technical skills have served in 39 nations for 3-6 month assignments investing nearly 200,000 hours of skills-based service to help increase the capacity of nonprofits organizations providing health care to the underserved (in the reporting period, 54 Global Health Fellows were deployed).

Pages